Profile data is unavailable for this security.
About the company
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
- Revenue in USD (TTM)162.00k
- Net income in USD-23.94m
- Incorporated1984
- Employees8.00
- LocationEterna Therapeutics Inc1035 Cambridge Street, Suite 18ACAMBRIDGE 02141United StatesUSA
- Phone+1 (212) 582-1199
- Fax+1 (302) 655-5049
- Websitehttps://eternatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NuCana PLC (ADR) | 0.00 | -36.84m | 4.92m | 25.00 | -- | 0.9902 | -- | -- | -230.37 | -230.37 | 0.00 | 2.19 | 0.00 | -- | -- | 0.00 | -91.91 | -41.01 | -177.64 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0689 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.37m | 5.08m | 8.00 | -- | 0.3144 | -- | -- | -14.98 | -14.99 | 0.00 | 15.49 | 0.00 | -- | -- | 0.00 | -58.66 | -- | -62.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 5.52m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Yubo International Biotech Ltd | 454.29k | -1.42m | 5.52m | 18.00 | -- | -- | -- | 12.16 | -0.0118 | -0.0118 | 0.0038 | -0.0211 | 0.2462 | 0.5986 | 3.49 | 25,238.33 | -82.33 | -- | -- | -- | 80.30 | -- | -334.36 | -- | 0.1707 | -4,795.69 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Clearmind Medicine Inc | 0.00 | -8.44m | 5.68m | -- | -- | 1.60 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
| Eterna Therapeutics Inc | 162.00k | -23.94m | 5.68m | 8.00 | -- | -- | -- | 35.07 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 5.89m | 3.00 | -- | 0.1758 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 5.97m | 3.00 | -- | -- | -- | -- | -12.75 | -12.75 | 0.00 | -10.90 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -12.19m | 6.08m | 4.00 | -- | 0.9536 | -- | -- | -5.26 | -5.30 | 0.00 | 0.9961 | 0.00 | -- | -- | 0.00 | -279.27 | -182.35 | -320.96 | -235.45 | -- | -- | -- | -- | -- | -14.25 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 6.22m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.52m | -4.70m | 6.24m | 4.00 | -- | 0.8374 | -- | 2.48 | -3.05 | -3.05 | 1.64 | 4.83 | 0.2314 | -- | -- | 630,087.50 | -43.12 | -48.91 | -48.61 | -52.82 | -- | -- | -186.33 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 6.24m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 6.41m | 7.00 | -- | 1.59 | -- | 163.87 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.11m | -10.16m | 6.50m | 13.00 | -- | 0.6348 | -- | 2.09 | -39.72 | -39.72 | 2.31 | 2.41 | 0.2579 | 1.92 | 8.60 | 239,366.90 | -84.45 | -71.59 | -156.10 | -144.36 | 45.81 | -- | -327.50 | -565.48 | 1.42 | -- | 0.0592 | -- | 147.58 | 596.39 | 4.47 | -- | -- | -- |
Data as of Oct 10 2024. Currency figures normalised to Eterna Therapeutics Inc's reporting currency: US Dollar USD
7.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cypress Point Wealth Management LLCas of 30 Jun 2024 | 94.38k | 1.74% |
| Naviter Wealth LLCas of 30 Jun 2024 | 78.80k | 1.46% |
| Sippican Capital Advisors LLCas of 30 Jun 2024 | 72.80k | 1.35% |
| Corient Private Wealth LLCas of 31 Mar 2024 | 50.40k | 0.93% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 26.10k | 0.48% |
| Geode Capital Management LLCas of 30 Jun 2024 | 23.72k | 0.44% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 15.62k | 0.29% |
| Avidian Wealth Solutions LLCas of 30 Jun 2024 | 14.80k | 0.27% |
| Citadel Securities LLCas of 31 Mar 2024 | 10.09k | 0.19% |
| Baldwin Brothers LLCas of 30 Jun 2024 | 8.54k | 0.16% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
